Navigation Links
KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Date:11/20/2007

Second Quarter Net Revenues Up 61%, Six-Month Net Revenues Up 40% ETHEX Corporation Net Revenues Up 102% for Second Quarter and 67% for Six

Months Ther-Rx Corporation Net Revenues Up 13% for Second Quarter and 14% for Six

Months

ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today reported preliminary financial results reflecting strong revenue and earnings growth for the second quarter and first six months of fiscal 2008 ended September 30, 2007. The results reflected accelerated growth of the Company's generic/non-branded subsidiary, ETHEX Corporation, and continued growth at the Company's branded subsidiary, Ther-Rx Corporation.

All financial data presented herein is preliminary and subject to change until completion of our consolidated financial statements for all such periods, which is dependent on the completion of our previously announced restatement of the Company's financial statements for fiscal years 1996 through 2006 and the quarter ended June 30, 2006, as well as the completion of the Company's consolidated financial statements for September 30 and December 31, 2006 and the fiscal year ended March 31, 2007. The Company was not able to file its Form 10-Q for the quarter ended September 30, 2007 with the Securities and Exchange Commission in a timely manner. In addition, the Company also has not filed its September 30 and December 31, 2006 Form 10-Q's, its March 31, 2007 Form 10-K and its June 30, 2007 Form 10-Q. The restatement, which resulted from an investigation by a special committee of independent members of the Board of Directors into the Company's former stock option grant practices, is in process. The Company will file the affected reports promptly upon completion.

Second Quarter Results

Net revenues for the second quarter increased 61% to $175.4 million, compared to $108.8 million for the second qua
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Shimadzu ... new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning ... instrument is ideal for applications in a variety ... science. , The user-friendly UV-1280 enables intuitive operation, ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... 2015 Pipette.com has added the ... comprehensive portfolio of Eppendorf products. , The Eppendorf Centrifuge ... Centrifuge 5424/5424 R and receive the following:, ... plus or Eppendorf Reference 2 ,     3 ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... ... Coverage, ... biopharmaceutical company focusing on the development of,novel, proprietary antibody-based products for ... developed,using BiTE(R) technology will be reported at the joint international,meeting of ...
... N.C., Oct. 23 Coordinating and timing,activities is ... the results of clinical trials. Marketers, who have ... trials,need to "worry about competitors stealing your thunder, ... was about," states one,interviewed executive. According to ...
... 22, 2007 In a major feat of nanotechnology ... with a wide-range of potential applications in chemistry, biology ... the device is capable of resolving the chemical composition ... with unprecedented detail. , Spearheaded by graduate students Nanfang ...
Cached Biology Technology:Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 2Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 3Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 4Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 5Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2Harvard University engineers demonstrate quantum cascade laser nanoantenna 2
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... ID Technology Now Embedded in a Fully Flexible ... ... Dec. 5 Fidelica Microsystems, Inc., a,pioneering developer of ... company,s FSC-3012 Biometrically,Authenticated Smart Card. This biometrically-authenticated credential,features a ...
... prices rise, the costs of lower-calorie foods are rising the ... the December issue of the Journal of the American Dietetic ... other low-calorie foods have jumped nearly 20 percent in the ... may be moving out of the reach of some American ...
... so that they will rethink how an object works ... using that object, according to a Yale study today ... Even when you add time pressure, or warn the ... unable to avoid reproducing the adults irrelevant actions, said ...
Cached Biology News:Fidelica Microsystems Announces Biometrically-Authenticated Smart Card 2Price of lower-calorie foods rising drastically, researchers find 2Humans appear hardwired to learn by 'over-imitation' 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: